Jefferson Health

Physician Profile

Scott Waldman, MD

Academic Title: Professor
Chair, Pharmacology & Experimental Therapeutics

Specialties
Clinical Pharmacology (Not Accepting New Patients)

Office Locations

Philadelphia
132 S. 10th Street
Main Bldg., Ste 1170
Philadelphia PA 19107
Phone: (215) 955-6086
Fax: (215) 955-5681

Board Certifications

  • Internal Medicine
  • Clinical Pharmacology

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital

Education

  • Stanford University School of Medicine, Medical School

Internship

  • Stanford University Hospital

Residency

  • Stanford University Hospital

Recent Publications

A survey of physician receptivity to molecular diagnostic testing and readiness to act on results for early-stage colon cancer patients

Guanylyl cyclase C signaling axis and colon cancer prevention

Guanylyl cyclase C hormone axis at the intersection of obesity and colorectal cancer

Targeting guanylate cyclase C in colorectal cancer: Where are we now?

GUCY2C ligand replacement to prevent colorectal cancer

Big data transforms discoveryutilization therapeutics continuum

Obesity-induced colorectal cancer is driven by caloric silencing of the guanylin-GUCY2C paracrine signaling axis

Bioinnovation Enterprise: An Engine Driving Breakthrough Therapies

Intestinal enteroids model guanylate cyclase C-dependent secretion induced by heat-stable enterotoxins

Guanylyl cyclase C as a biomarker

CD19-targeted nanodelivery of doxorubicin enhances therapeutic efficacy in B-cell acute lymphoblastic leukemia

Clinical pharmacology & therapeutics: The next five years

Companion diagnostics at the intersection of personalized medicine and healthcare delivery

A novel CDX2 isoform regulates alternative splicing

Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C

Managing the innovation supply chain to maximize personalized medicine

Molecular insights provide the critical path to disease mitigation

Selective antigen-specific CD4+ T-cell, but not CD8+ T- or B-cell, tolerance corrupts cancer immunotherapy

Antiobesity pharmacotherapy: New drugs and emerging targets

Policies to aid the adoption of personalized medicine